💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Drugmakers should cut COVID-19 vaccine prices for Africa - Africa CDC

Published 12/17/2020, 09:33 AM
Updated 12/17/2020, 09:35 AM
© Reuters. FILE PHOTO: John Nkengasong, Africa’s Director of Centers for Disease Control (CDC), speaks during a news conference on coronavirus at the African Union Headquarters in Addis Ababa

By Omar Mohammed

NAIROBI (Reuters) - Pharmaceutical companies should sell COVID-19 vaccines to African countries at discounted rates and allow them to be produced locally to potentially cut costs, the head of the continent's disease control body said on Thursday.

Africa is aiming to vaccinate up to 60% of its 1.3 billion people in the next two years, but may need several years of inoculations, John Nkengasong, director of the Africa Centres for Disease Control and Prevention (CDC) told reporters.

How frequently people will need vaccinations against COVID-19 remains uncertain, he said.

"Because of this, local manufacturing becomes imperative so that we can meet our goals," he said.

Many African states are relying on COVAX, a global COVID-19 vaccine allocation plan co-led by the World Health Organization (WHO), which is working to lower prices for poor and middle income countries.

But the Africa CDC expects to receive only 20% of its vaccine needs through COVAX, and also needs money to distribute the vaccine.

"The COVAX facility does not take care of delivery, it takes care of the buying of the vaccines. But the greatest challenge for any vaccination programme is how do you deliver it to the needy in a timely fashion," Nkengasong said,

He added the continent was working with Afreximbank and the World Bank to see how to raise funds to buy and deliver vaccines.

In November, South African President Cyril Ramaphosa, who is also the chairperson of the African Union, said $12 billion was needed for the vaccination programme.

On Thursday, GAVI, a vaccines alliance that co-leads COVAX with the WHO, said COVAX was on track with its goal to secure 2 billion COVID-19 vaccine doses by the end of 2021.

"COVAX has met its initial fundraising target and is making excellent progress in negotiating deals with manufacturers," said Thabani Maphosa, a managing director at GAVI.

© Reuters. FILE PHOTO: John Nkengasong, Africa’s Director of Centers for Disease Control (CDC), speaks during a news conference on coronavirus at the African Union Headquarters in Addis Ababa

The Africa CDC said on Thursday a survey it conducted with the London School of Hygiene and Tropical Medicine showed nearly 80% of Africans would take a COVID-19 vaccine.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.